Dolby Laboratories filings document the regulatory disclosures of a technology licensing and cinema-products company whose Class A common stock trades on the New York Stock Exchange under DLB. Recent Form 8-K reports furnish quarterly and annual financial results, dividend declarations for Class A and Class B common stock, and related exhibits.
The company’s proxy and governance filings cover director elections, advisory executive-compensation votes, auditor ratification and executive incentive compensation arrangements. The filings also describe Dolby’s dual-class voting structure, with Class A and Class B common stock voting together on most stockholder matters except where law requires otherwise.
Vanguard Portfolio Management reported beneficial ownership of 5,019,900 shares of Dolby Laboratories Inc. common stock, equal to 8.24% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 5,019,900 shares and sole voting power for 49,076 shares. The statement clarifies these holdings reflect securities managed across Vanguard affiliates and funds.
The Bank of New York Mellon Corporation amended its Schedule 13G to report passive ownership stakes in Dolby Laboratories, Inc. Class A common stock. The amendment lists specific subsidiaries with their reported beneficial holdings and percentage of the class, including The Bank of New York Mellon with 4,499,820 shares (7.4%), BNY Mellon IHC, LLC with 3,791,098 shares (6.2%), MBC Investments Corp with 3,791,098 shares (6.2%), and Newton Investment Management North America, LLC with 3,275,399 shares (5.4%).
The filing states these holdings are held in various fiduciary capacities by BNY Mellon and its subsidiaries; no single third party is reported as having more than 5% beneficial interest in the securities for purposes of Item 6.
Dolby Laboratories director Emily Rollins reported an open-market sale of 1,000 shares of Class A common stock at $60.08 per share on April 1, 2026. After this transaction, she directly holds 12,541 shares of Class A common stock.
Her post-transaction holdings include 3,908 shares underlying restricted stock units that remain subject to forfeiture until they vest, meaning part of her reported position is tied to future service or performance conditions rather than fully vested stock.
DLB submitted a Rule 144 notice reporting proposed sales of common stock totaling 1,000 shares. The filing lists 245 shares dated 02/06/2023 and 755 shares dated 02/05/2024 as restricted stock being sold through Morgan Stanley Smith Barney LLC. The securities are listed on NYSE.
The Vanguard Group filed Amendment No. 14 to a Schedule 13G/A reporting Dolby Laboratories Inc. common stock and states it beneficially owns 0 shares representing 0% of the class.
The filing explains an internal realignment effective January 12, 2026, that disaggregated certain Vanguard subsidiaries and business divisions for reporting under SEC Release No. 34-39538; the filing is signed by Ashley Grim, Head of Global Fund Administration.
Dolby Laboratories, Inc. insider reporting centers on indirect holdings controlled through family trusts. On February 25, 2026, the Dagmar Dolby Trust contributed 1,000,000 shares of Class B Common Stock to a newly formed grantor retained annuity trust, described as a transfer for no value for tax and estate planning purposes. On the same date, the Dagmar Dolby Trust also converted 10,000 shares of Class B into 10,000 shares of Class A and gifted all those Class A shares to an unaffiliated charitable organization at no cost. Voting and investment power over various Class B positions is allocated among special trustees and LLC managers, and Dagmar Dolby disclaims beneficial ownership beyond her pecuniary interest.
Dolby Laboratories, Inc. executive Shriram Revankar reported an open-market sale of company stock. On 02/17/2026, he sold 3,000 shares of Class A common stock at $66.14 per share. After this transaction, he beneficially owned 83,218 Class A shares, including 59,172 shares underlying restricted stock units that may be forfeited if they do not vest.
Dolby Laboratories executive Ryan Nicholson, VP, CAO and Corporate Controller, reported an option exercise and share sale. On 02/13/2026 he exercised an employee stock option for 2,667 shares of Class A common stock at an exercise price of $45.50 per share, converting the derivative into common stock.
That same day, he sold 2,667 Class A shares in open-market transactions at a weighted average price of $66.3752 per share, in trades ranging from $66.37 to $66.39. After these transactions, he directly owns 36,956 Class A shares, including 19,303 shares underlying restricted stock units that remain subject to forfeiture until they vest.
Dolby Laboratories has a holder planning to sell 3,000 shares of its common stock under Rule 144. The planned sale through Morgan Stanley Smith Barney has an aggregate market value of $198,420.00, with 60,884,768 Dolby common shares outstanding and trading on the NYSE.
The 3,000 shares to be sold were acquired as restricted stock from the issuer on 05/16/2024. The form also notes that the same person, identified as Revankar, sold 3,000 Dolby common shares on 11/21/2025 for gross proceeds of $196,650.00.
Dolby Laboratories’ controlling shareholders report a small reduction in their stake driven by charitable giving. An amended beneficial ownership report from Dagmar Dolby, family members and related trusts shows their combined percentage of outstanding Class A common stock has fallen by more than one percent.
The change comes mainly from gifts of 43,500 Class A shares by the Dagmar Dolby Fund and 890,000 Class A shares by the Dagmar Dolby Trust, partially offset by 3,140 Class A shares issued to David E. Dolby upon vesting of restricted stock units. After these moves, Dagmar Dolby beneficially owns 34,368,358 shares of Class A (assuming conversion of Class B), or 36.0% of that class, representing 84.0% of total voting power. David E. Dolby beneficially owns 33,615,951 such shares, or 35.2% of Class A, representing 82.3% of total voting power.